DK1187603T3 - Kombinationsterapi tl at bevirke vægttab og at behandle obesitet - Google Patents

Kombinationsterapi tl at bevirke vægttab og at behandle obesitet

Info

Publication number
DK1187603T3
DK1187603T3 DK00939884T DK00939884T DK1187603T3 DK 1187603 T3 DK1187603 T3 DK 1187603T3 DK 00939884 T DK00939884 T DK 00939884T DK 00939884 T DK00939884 T DK 00939884T DK 1187603 T3 DK1187603 T3 DK 1187603T3
Authority
DK
Denmark
Prior art keywords
weight loss
combination therapy
treat obesity
cause weight
phentermine
Prior art date
Application number
DK00939884T
Other languages
English (en)
Inventor
Thomas Najarian
Original Assignee
Vivus Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Vivus Inc filed Critical Vivus Inc
Application granted granted Critical
Publication of DK1187603T3 publication Critical patent/DK1187603T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Diabetes (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Emergency Medicine (AREA)
  • Endocrinology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pulmonology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Plant Substances (AREA)
DK00939884T 1999-06-14 2000-06-14 Kombinationsterapi tl at bevirke vægttab og at behandle obesitet DK1187603T3 (da)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US13902299P 1999-06-14 1999-06-14
US17856300P 2000-01-26 2000-01-26
US18126500P 2000-02-09 2000-02-09
PCT/US2000/016434 WO2000076493A1 (en) 1999-06-14 2000-06-14 Combination therapy for effecting weight loss and treating obesity

Publications (1)

Publication Number Publication Date
DK1187603T3 true DK1187603T3 (da) 2007-12-17

Family

ID=27385274

Family Applications (1)

Application Number Title Priority Date Filing Date
DK00939884T DK1187603T3 (da) 1999-06-14 2000-06-14 Kombinationsterapi tl at bevirke vægttab og at behandle obesitet

Country Status (10)

Country Link
EP (5) EP2305228B1 (da)
AT (1) ATE369126T1 (da)
AU (1) AU770068B2 (da)
CA (2) CA2377330C (da)
CY (1) CY1106974T1 (da)
DE (1) DE60035870T2 (da)
DK (1) DK1187603T3 (da)
ES (4) ES2542868T3 (da)
PT (1) PT1187603E (da)
WO (1) WO2000076493A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7056890B2 (en) 1999-06-14 2006-06-06 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7659256B2 (en) 1999-06-14 2010-02-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US7674776B2 (en) 1999-06-14 2010-03-09 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
US20080103179A1 (en) * 2006-10-27 2008-05-01 Tam Peter Y Combination Therapy
US7553818B2 (en) 1999-06-14 2009-06-30 Vivus, Inc. Combination therapy for effecting weight loss and treating obesity
EP1309324B1 (en) 2000-07-07 2006-03-22 Ortho-McNeil Pharmaceutical, Inc. Anticonvulsant derivatives useful for treating and preventing the development of type ii diabetes mellitus and syndrome x
US6191117B1 (en) * 2000-07-10 2001-02-20 Walter E. Kozachuk Methods of producing weight loss and treatment of obesity
RU2003112618A (ru) * 2000-10-30 2004-09-27 Орто-Макнейл Фармасьютикал, Инк. (Us) Комбинированная терапия, включающая антидиабетические и противосудорожные средства
EP1345602B1 (en) * 2000-11-30 2010-07-21 Novodermix International Limited Wound healing
EP1496838B1 (en) 2002-03-12 2010-11-03 Merck Sharp & Dohme Corp. Substituted amides
US7109198B2 (en) 2002-05-17 2006-09-19 Duke University Method for treating obesity
BR0316853A (pt) * 2002-12-13 2005-10-18 Cilag Ag Formulações de topiramato estáveis
EP2316456B1 (en) 2003-04-29 2017-06-14 Orexigen Therapeutics, Inc. Compositions for affecting weight loss comprising an opioid antagonist and bupropion
EP1734955A2 (en) 2004-01-13 2006-12-27 Duke University Compositions of an anticonvulsant and an antipsychotic drug for affecting weigt loss
US7713959B2 (en) 2004-01-13 2010-05-11 Duke University Compositions of an anticonvulsant and mirtazapine to prevent weight gain
MY147767A (en) 2004-06-16 2013-01-31 Janssen Pharmaceutica Nv Novel sulfamate and sulfamide derivatives useful for the treatment of epilepsy and related disorders
JP2008545650A (ja) 2005-05-20 2008-12-18 ジヤンセン・フアーマシユーチカ・ナームローゼ・フエンノートシヤツプ スルファミド誘導体の製造方法
EP1951212A2 (en) 2005-11-22 2008-08-06 Orexigen Therapeutics, Inc. Compositions and methods for increasing insulin sensitivity
US8492431B2 (en) 2005-12-19 2013-07-23 Janssen Pharmaceutica, N.V. Use of benzo-fused heterocycle sulfamide derivatives for the treatment of obesity
US8716231B2 (en) 2005-12-19 2014-05-06 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of pain
US8937096B2 (en) 2005-12-19 2015-01-20 Janssen Pharmaceutica Nv Use of benzo-fused heterocyle sulfamide derivatives for the treatment of mania and bipolar disorder
US8497298B2 (en) 2005-12-19 2013-07-30 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for lowering lipids and lowering blood glucose levels
US8691867B2 (en) 2005-12-19 2014-04-08 Janssen Pharmaceutica Nv Use of benzo-fused heterocycle sulfamide derivatives for the treatment of substance abuse and addiction
EA200870556A1 (ru) 2006-05-19 2009-06-30 Янссен Фармацевтика Н.В. Комбинированная терапия в лечении эпилепсии и родственных расстройств
US8916195B2 (en) 2006-06-05 2014-12-23 Orexigen Therapeutics, Inc. Sustained release formulation of naltrexone
US7780730B2 (en) 2006-09-25 2010-08-24 Iyad Saidi Nasal implant introduced through a non-surgical injection technique
KR20090090316A (ko) 2006-11-09 2009-08-25 오렉시젠 세러퓨틱스 인크. 체중 감량 약물을 투여하기 위한 단위 용량 팩키지 및 투여 방법
TW201811315A (zh) * 2006-11-09 2018-04-01 美商歐瑞根治療有限公司 層狀醫藥調配物
AU2014213552B2 (en) * 2007-06-13 2016-11-24 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors in combination with a sympathomimetic amine
US8071557B2 (en) * 2007-06-13 2011-12-06 Vivus, Inc. Treatment of pulmonary hypertension with carbonic anhydrase inhibitors
CA2725930A1 (en) 2008-05-30 2009-12-30 Orexigen Therapeutics, Inc. Methods for treating visceral fat conditions
US20090304789A1 (en) 2008-06-09 2009-12-10 Thomas Najarian Novel topiramate compositions and an escalating dosing strategy for treating obesity and related disorders
US8580298B2 (en) 2008-06-09 2013-11-12 Vivus, Inc. Low dose topiramate/phentermine composition and methods of use thereof
NZ590682A (en) 2008-06-23 2012-09-28 Janssen Pharmaceutica Nv Crystalline form of (2S)-(-)-N-(6-chloro-2,3-dihydro-benzo[1,4]dioxin-2-ylmethyl)-sulfamide
US8815939B2 (en) 2008-07-22 2014-08-26 Janssen Pharmaceutica Nv Substituted sulfamide derivatives
US9597220B2 (en) 2008-11-19 2017-03-21 Spirox, Inc. Apparatus and methods for correcting nasal valve collapse
ES2762113T3 (es) 2010-01-11 2020-05-22 Nalpropion Pharmaceuticals Inc Métodos de proporcionar terapia de pérdida de peso en pacientes con depresión mayor
WO2013028909A1 (en) * 2011-08-25 2013-02-28 Sova Pharmaceuticals, Inc. Combination therapy for the treatment of sleep-related breathing disorders
EP4104824A1 (en) 2012-06-06 2022-12-21 Nalpropion Pharmaceuticals LLC Composition for use in a method of treating overweight and obesity in patients with high cardiovascular risk
CA3161309A1 (en) 2013-02-27 2014-09-04 Spirox, Inc. Nasal implants and systems and methods of use
WO2014134477A1 (en) * 2013-02-28 2014-09-04 Livelight Llc Methods and systems for treating overweight individuals
US10226062B2 (en) 2013-12-05 2019-03-12 Givaudan Sa Organic compounds
WO2016033196A1 (en) 2014-08-26 2016-03-03 Spirox, Inc. Nasal implants and systems and method of use
CN113349985A (zh) 2015-09-25 2021-09-07 斯贝洛克斯公司 鼻植入物和***及使用方法

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4513006A (en) 1983-09-26 1985-04-23 Mcneil Lab., Inc. Anticonvulsant sulfamate derivatives
FR2684101B1 (fr) * 1991-11-22 1993-12-31 Adir Cie Nouveaux derives de benzoate d'ethanolamine, leur procede de preparation et les compositions pharmaceutiques les renfermant.
US5384327A (en) 1992-12-22 1995-01-24 Mcneilab, Inc. Anticonvulsant sorbopyranose sulfamates
US5543405A (en) * 1993-10-22 1996-08-06 Keown; Wendy J. Composition and method for weight reduction and long term management of obesity
US5498629A (en) 1993-12-23 1996-03-12 Ortho Pharmaceutical Corporation Anticonvulsant pseudofructopyranose sulfamates
US5753694A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating amyotrophic lateral sclerosis (ALS)
US5753693A (en) 1996-06-28 1998-05-19 Ortho Pharmaceutical Corporation Anticonvulsant derivatives useful in treating manic-depressive bipolar disorder
US5795895A (en) 1997-06-13 1998-08-18 Anchors; J. Michael Combination anorexiant drug therapy for obesity using phentermine and an SSRI drug
UA65607C2 (uk) * 1998-03-04 2004-04-15 Орто-Макнейл Фармацевтикал, Інк. Фармацевтична композиція (варіанти) та спосіб її приготування

Also Published As

Publication number Publication date
ES2291215T3 (es) 2008-03-01
EP2305228A1 (en) 2011-04-06
EP1187603A1 (en) 2002-03-20
CA2377330C (en) 2009-11-24
EP2305226A1 (en) 2011-04-06
EP2308481A1 (en) 2011-04-13
PT1187603E (pt) 2007-11-16
DE60035870T2 (de) 2008-05-08
ES2542892T3 (es) 2015-08-12
EP1187603A4 (en) 2004-02-11
ES2542891T3 (es) 2015-08-12
CA2686633A1 (en) 2000-12-21
CY1106974T1 (el) 2012-09-26
EP2305227A1 (en) 2011-04-06
ES2542868T3 (es) 2015-08-12
ATE369126T1 (de) 2007-08-15
AU5489600A (en) 2001-01-02
WO2000076493A1 (en) 2000-12-21
EP2305228B1 (en) 2015-05-06
EP2305227B1 (en) 2015-05-06
EP2308481B1 (en) 2015-05-06
DE60035870D1 (de) 2007-09-20
CA2377330A1 (en) 2000-12-21
AU770068B2 (en) 2004-02-12
EP1187603B1 (en) 2007-08-08
EP2305226B1 (en) 2015-05-06

Similar Documents

Publication Publication Date Title
DK1187603T3 (da) Kombinationsterapi tl at bevirke vægttab og at behandle obesitet
NO2013017I2 (no) (a)dekstrometorfan eller et farmasøytisk akseptabelt salt derav, for eksempel dekstrometorfanhydrobromid og (b) quinidin eller etfarmasøytisk akseptabelt salt derav, for eksempel quinidinsulfat
CY1107314T1 (el) Μεθοδος θεpαπευτικης αγωγης ασθενων προσβεβλημενων με σκληρυνση κατα πλακας χρησιμοποιωντας συναινετικη ιντepφepονη
DK1333887T3 (da) Kombinationsbehandling omfattende antidiabetiske og antikonvulsive midler
DK0841949T3 (da) Anvendelse af saccharid-konjugater
PT971713E (pt) Utilizacao de inibidores da colinesterase para tratamento de desordens da atencao
DK0754176T3 (da) Hidtil ukendte carbamater og urinstoffer som modifikatorer for multidrugsresistens
BR0211062A (pt) Combinações para o tratamento de distúrbios inflamatórios
NO20013155L (no) Fremgangsmate ved anvendelse av cyklooksygenase-2-inhibitor og ett eller flere antineoplastiske midler som enkombinasjonsterapi i behandlingen av neoplasi
CY1113610T1 (el) Συνθεσεις και μεθοδοι για αγωγη μιτοχονδριακων παθησεων
TR199801315T2 (xx) X sendromunun tedavisi i�in bir ppar-alpha ve ppar-gamma antagonistinin kullan�lmas�.
BR9814923A (pt) Método para tratamento de doença de alzheimer
DK0858504T3 (da) Diagnostiske midler mod og behandlinger af periodontale sygdomme
EP0824917A3 (en) Use of a serotonin 5-HTlf agonist in the manufacture of a medicament for treating or ameliorating the symptoms of common cold or allergic rhinitis
DK1032556T3 (da) Farmaceutisk aktive forbindelser og anvendelsesfremgangsmåder
NO994165L (no) Anvendelse av deskarboetoksyloratadin for fremstilling av et medikament for behandling av urininkontinens, reisesyke og svimmelhet
TR199801289T2 (en) Terap�tik bile�ikler.
NO984160L (no) FremgangsmÕte for behandling eller forebyggelse av interstitiell cystitt
ATE306977T1 (de) Schaukel für behinderte
ATE242642T1 (de) Kombinationstherapie für lymphoproliferative krankheiten
NO20053023L (no) Synergistisk kombinasjon omfattende roflumilas og (R,R)-formoterol
DE69303305D1 (de) Mittel zur Behandlung chronischer Ermüdungserscheinungen
EP1825851A3 (en) Combination therapy for effecting weight loss and treating obesity
DK1156795T3 (da) Anvendelse af ravsyre eller salte deraf, og fremgangsmåde til behandling af insulinresistens
BR0012318A (pt) Compostos semelhantes a amino ceramida e métodos terapêuticos de uso